Date:2/25/2013

Cayman Islands on March 8, 2013 will be entitled to vote at the EGM and any adjourned or postponed meeting thereof. The record date for ADS holders entitled to instruct JPMorgan Chase Bank, N.A., the ADS depositary, to vote the shares represented by the ADSs is the close of business in New York City on February 25, 2013. Additional information regarding the EGM and the Merger Agreement can be found in the Transaction Statement on Schedule 13E-3 and the proxy statement attached as Exhibit (a)-(1) thereto, as amended, filed with the U.S. Securities and Exchange Commission (the "SEC"), which can be obtained from the SEC's website (www.sec.gov). INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS.

This announcement is neither a solicitation of a proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that have been or will be made with the SEC.

About ShangPharma Corporation

ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. The Company's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For m
'/>"/>

SOURCE ShangPharma Corporation Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. ShangPharma Announces Third Quarter 2012 Results
2. ShangPharma to Report Third Quarter 2012 Financial Results on November 20, 2012
3. ShangPharma and Harbour Antibodies Announce Licensing Agreement
4. ShangPharma Announces Second Quarter 2012 Results
5. ShangPharma to Report Second Quarter 2012 Financial Results on August 20, 2012
6. ShangPharma Independent Committee Appoints Financial Advisor
7. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
8. ShangPharma Announces Receipt of "Going Private" Proposal at $8.50 to $9.50 Per ADS
9. ShangPharma Announces First Quarter 2012 Results
10. ShangPharma to Report First Quarter 2012 Financial Results on May 17, 2012
11. ShangPharma Corporation Files 2011 Annual Report on Form 20-F